BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29874985)

  • 1. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
    Chae H; Cho H; Yoo C; Kim KP; Jeong JH; Chang HM; Kang J; Lee HC; Lim YS; Kim KM; Shim JH; Lee SS; Park DH; Song TJ; Hwang S; Song GW; Moon DB; Lee YJ; Lee JH; Ryoo BY
    Int J Biol Markers; 2018 Nov; 33(4):432-438. PubMed ID: 29874985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
    Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
    BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.
    Lee SY; Kim HS; Choi YJ; Park KH; Shin SW; Kim YH; Tae Kim S
    Am J Ther; 2016; 23(6):e1449-e1455. PubMed ID: 25285672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
    Cho H; Yoo C; Kim KP; Jeong JH; Kang J; Chang HM; Lee SS; Park DH; Song TJ; Lee SK; Kim MH; Lee HC; Lim YS; Kim KM; Shim JH; Hwang S; Song GW; Moon DB; Lee JH; Lee YJ; Ryoo BY
    Invest New Drugs; 2018 Jun; 36(3):496-502. PubMed ID: 29192354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
    Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
    Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
    Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
    Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis.
    Schweitzer N; Weber T; Kirstein MM; Fischer M; Kratzel AM; Reineke-Plaaß T; Lehner F; Manns MP; Vogel A
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1347-1355. PubMed ID: 28314929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
    Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
    Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS
    Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study.
    Shin DW; Kim MJ; Lee JC; Kim J; Woo SM; Lee WJ; Lee KH; Hwang JH
    Am J Clin Oncol; 2020 Jun; 43(6):422-427. PubMed ID: 32118610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
    Nooijen LE; Franken LC; Belkouz A; Oulad Abdennabi I; Besselink MG; Busch OR; Swijnenburg RJ; Klümpen HJ; Erdmann JI
    Am J Clin Oncol; 2021 Oct; 44(10):526-532. PubMed ID: 34469345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
    Butthongkomvong K; Sirachainan E; Jhankumpha S; Kumdang S; Sukhontharot OU
    Asian Pac J Cancer Prev; 2013; 14(6):3565-8. PubMed ID: 23886146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.
    Hong MJ; Cheon YK; Lee EJ; Lee TY; Shim CS
    Gut Liver; 2014 May; 8(3):318-23. PubMed ID: 24827630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
    Marciano R; Servetto A; Bianco C; Bianco R
    J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.